To use the Medicare GLP-1 Bridge benefit, patients generally need to meet all of the following: Be enrolled in Medicare Part D (a standalone prescription drug plan or Medicare Advantage plan with prescription drug coverage) Be at least 18 years old AND meet one of three BMI-based eligibility tiers (more restrictive than the general FDA label): Tier 1: BMI of 35 or higher (no additional conditions required), or Tier 2: BMI of 30 or higher WITH heart failure with preserved ejection fraction, OR uncontrolled hypertension (systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite treatment with two antihypertensive medications), OR chronic kidney disease stage 3a or above, or Tier 3: BMI of 27 or higher WITH prediabetes (per American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease Be using the medication in combination with current and ongoing lifestyle modification including structured nutrition and physical activity Have a prescription from a qualified prescriber (any licensed clinician with prescribing authority can prescribe

The sun will have a counteractive effect because it increases eumelanin production and darkens skin tone
By distribution channel, the online pharmacies segment is expected to expand at the fastest CAGR during 2025-2034
Largest seizure of unlicensed weight loss medicines, May 2026
Compound: Melanotan II (MT-II) Concentration: 10mg per vial Format: Lyophilized White Powder (Strictly for In-Vitro Laboratory Use) Chemical Classification: Non-Selective Melanocortin Receptor Agonist Chemical Profile: Melanotan II (MT-II) is a synthetic cyclic heptapeptide derived from the alpha-melanocyte-stimulating hormone (-MSH) structure
Cyanocobalamin a synthetic form of B12 that requires other nutrients from the body to make it bioavailable